Director, Business Development for Oncology Therapy Area
Active and successful business development for oncology and other core therapy areas will be an increasing area of focus for GSK R&D. On April 18, 2018 GSK announced the appointment of Kevin Sin as SVP of Worldwide Business Development (WWBD). Kevin was previously VP and Global Head of Oncology Business Development at Genentech and will report to Hal Barron, GSK's Chief Scientific Officer and President of Research and Development. Importantly, the central role of business development as part of the overall GSK oncology strategy was endorsed during the May Board of Directors meeting.
The role is a strategic business development role that will report to the Oncology Business Development Head who is a member of the Oncology TA Leadership Team (LT) and is accountable for 1) setting the BD strategy with the TA Head/LT Members and 2) executing the strategy and deals in collaboration with relevant TA, R&D, Commercial and WWBD functions and team members.
The current BD strategy is modular and is comprised of 3 pillars:
1. Accessing assets that could accelerate the pace of market re-entry and/or strengthen our position in cancer epigenetics, immuno-oncology, and oncology cell therapies
2. To enhance our experimental medicine activity for internal assets via collaborations
3. Maximize the value of existing alliances
The candidate will be accountable for leading and managing all relevant activities necessary for delivering the BD strategy summarized above.
Specifically, for Pillar 1, the candidate will search out and keep pace with innovation by coordinating landscape sweeps, attending conferences, reviewing competitive intelligence and building relationships with key members of the oncology ecosystem (external and internal). In addition, the candidate will lead the selection and evaluation of prioritized opportunities, create preliminary business cases and communicate the potential value of a deal to relevant stakeholders (internal and external). Lastly, the candidate will drive deals to completion by managing the deal process in collaboration with relevant WWBD members (Scientific Licensing and Transactions), legal, Commercial and R&D.
For Pillar 2, the candidate will work closely with Project Leaders for internal assets to enable, via BD, experimental medicine activities including clinical data generation, biomarker innovation, etc. The candidate will drive forward the execution of definitive agreements by collaborating with legal and other functional experts.
For Pillar 3, the candidate will work closely with the Alliance Director and/or JSC chairperson to ensure that full value from existing alliances is realized (ie programs already under license or access to additional assets from the alliance company). The candidate will ensure, as needed, the execution of amendments or new definitive agreements by collaborating with legal and other functional experts. As GSK Oncology evolves, the candidate will directly contribute to the refreshing of the BD strategy by working closely with TA and Commercial Franchise team members.
An overaching accountability to the above is adequate and timely collection, organization and entry of key data summarizing interactions or other outputs. Moreover, the candidate is expected to build strong and credible relationships within the Oncology TA as well as WWBD. In this latter case, the candidate will participate and share learnings/suggestions in an effort to continously improve business development within GSK.
Lastly, at GSK, our values and expectations are at the heart of everything we do. They guide our actions and decision-making. At our core values are patient focus, integrity, respect for people and transparency. We expect our employees to share our values, to act transparently and with integrity at all times. In order to succeed at GSK, you need to demonstrate the following behavioral expectations of courage, personal development, accountability and teamwork in order to help GSK become the most innovative, high performing and trusted pharmaceutical company.
Overarching description is a 'soup to nuts' seasoned oncology generalist who can help to develop/deliver a strategy, source a wide range of opportunities and ensure a rapid and successful close while being able to articulate the strategic value within GSK as well as to the other party
• Masters of Science
• Significant experience working in industry (major pharma or biotechnology)
• Strong scientific/clinical experience in oncology and immunology. Firm understanding of cell biology/virology a plus
• Adequate commercial/market place awareness especially in oncology
o Competitive sets, treatment evolution for key tumor types, value drivers
• Previous direct experience in an oncology BD role that, ideally, includes both search/evaluate and transaction experience
o Track record identifying, assessing and advocating opportunities
o Established or growing external network, understanding of key external players
o Deal structure(s)/agreement savvy
o Firm grasp of financial valuation basics
• Experience and track record creating preliminary and full investment cases and communicating these to senior leaders (from one-to-one discussions to formal governance meetings)
• Experience leading matrix teams, particularly where participants may be from more senior levels of the organization (VP/SVP level)
• MD/PhD/PharmD +/- MBA
• Evidence of strong and effective written and verbal communication
• A demonstrated ability to autonomously manage workload and priorities and to reprioritize as the changing situation requires
• Evidence of scientific rigor in thinking, intellectual agility and empathy.
• Personal attributes: proactive, independent, courage to challenge the status quo, influencing without authority, ability to operate in ambiguity, solution-minded.
GSK Oncology is one of GSK Pharma's 4 core therapy areas and is considered a future growth driver for the company. In 2014, GSK divested its Oncology late stage development and commercial business (ie targeted therapies such as kinase inhibitors and other traditional anti-cancer agents) to Novartis. However, GSK retained its Oncology discovery/preclinical portfolio (comprised of innovative next generation anti-cancer agents) and infrastructure. Since 2014, GSK has progressed this innovative portfolio and has delivered over 9 novel assets into clinical development (alone or in partnership). Moreover, GSK Oncology has established a strong position and focus in three areas; namely, cancer epigenetics, immune-oncology and combinations, and oncology cell therapies (TCR-T and CAR-T).
The GSK Oncology vision is to maximize the survival of cancer patients by delivering transformational medicines alone or in combination. In addition to in-house discovery and development, the Therapy Area (TA) will rely on outside innovation to deliver this vision. Importantly, Oncology represents one of the most heavily invested and innovative therapy areas across the life sciences and Healthcare industry. The field is evolving at an unprecedented pace and, if leveraged/accessed properly via business development, is expected to contribute to the overall vision of GSK Oncology.
You may apply for this position online by selecting the Apply now button.
If you require an accommodation or other assistance to apply for a job at GSK, please contact the GSK HR Service Centre at 1-877-694-7547 (US Toll Free) or +1 801 567 5155 (outside US).
GSK is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive equal consideration for employment without regard to race, color, national origin, religion, sex, pregnancy, marital status, sexual orientation, gender identity/expression, age, disability, genetic information, military service, covered/protected veteran status or any other federal, state or local protected class.
Important notice to Employment businesses/ Agencies
GSK does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact GSK's commercial and general procurement/human resources department to obtain prior written authorization before referring any candidates to GSK. The obtaining of prior written authorization is a condition precedent to any agreement (verbal or written) between the employment business/ agency and GSK. In the absence of such written authorization being obtained any actions undertaken by the employment business/agency shall be deemed to have been performed without the consent or contractual agreement of GSK. GSK shall therefore not be liable for any fees arising from such actions or any fees arising from any referrals by employment businesses/agencies in respect of the vacancies posted on this site.
Please note that if you are a US Licensed Healthcare Professional or Healthcare Professional as defined by the laws of the state issuing your license, GSK may be required to capture and report expenses GSK incurs, on your behalf, in the event you are afforded an interview for employment. This capture of applicable transfers of value is necessary to ensure GSK's compliance to all federal and state US Transparency requirements. For more information, please visit GSK's Transparency Reporting For the Record site.
Meet Some of GlaxoSmithKline's Employees
Jasdeep finds diverse suppliers to build GSK’s pipeline. He organizes joint ventures with companies and negotiates pricing rates and payments to build a seamless supply system for GSK’s materials and products.
Back to top